Mr. Jack Kay - Chairman of the Board
"I have served as a director of Helix since 2005, and I look forward to becoming even more involved in the Company as its Chairman," said Mr. Kay. "Having worked in the pharmaceutical industry for over 45 years, and, since 1995, as President of Apotex Inc., I am fully aware of the challenges involved in bringing new drugs to market. I believe that Helix's management has done an admirable job in directing both L-DOS47 and Topical Interferon Alpha-2b through the challenging clinical trial regulatory approval process, including designing and undertaking the scientific, analytical and manufacturing work necessary to do so.
Given the nature of Helix's two lead compounds, this has not been an easy task, with some setbacks encountered along the way, typical of the drug development process. Having seen the Helix management team persevere through and overcome various setbacks, I am impressed with their creativity, ingenuity and drive that has allowed Helix to achieve the current stage of development of its two lead drug candidates. I am excited about Helix's next stage of development and about continuing to work with the Helix management team and its proposed new Board of Directors toward realizing our collective strategic vision to establish Helix as a leading developer of clinically proven, innovative cancer therapies."
Mr. Kay has a wealth of experience in the biopharmaceutical and pharmaceutical sectors. The Apotex Group is the largest Canadian-owned group of pharmaceutical companies. He has decades of senior operational, sales and marketing experience within the pharmaceutical industry. He is a director of several institutional and charitable organizations, including a director of Baycrest Hospital, and a past Chairman of the Humber River Regional Hospital, the International Schizophrenia Foundation, and the Canadian Generic Pharmaceutical Association. He is also a director of Cangene Corporation, a TSX traded public biopharmaceutical company.
Professor Kazimierz Roszkowski-Śliż - European Medical Director
"I, too, look forward to continuing on as part of the Helix team, as its European Medical Director," said Professor Kazimierz Roszkowski- Śliż. "Stepping down from the Board at the next Annual General Meeting in order to fulfill this specific role in Helix which is squarely within my area of expertise in the field of lung cancer and lung diseases, will enable me to concentrate my efforts for Helix for the foreseeable future on the further development of L-DOS47. I have been assisting Helix in this endeavor since becoming a director of the Company in 2009, and can echo what Jack Kay has said, that Helix's management has done an admirable job in developing its L-DOS47 and Topical Interferon Alpha-2b new drug candidates to their current stage, and I am excited about continuing to work with Helix's management team in my new capacity."
Professor Roszkowski-Śliż is an expert in the field of lung disease and lung cancers, and is a director at the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland, where he is also head of the clinical department. In addition, Professor Roszkowski-Śliż consults on lung disease issues for the Polish Ministry of Health. He received his M.D. from the Medical Academy in Warsaw and his Ph.D. from the Postgraduate Medical Center in Warsaw. He is an accomplished researcher with over 230 published papers.
Annual General Meeting
Helix may be facing a contested election for its board of directors (the "Board" or the "Board of Directors") at its upcoming Annual General Meeting, scheduled for January 30, 2012. Should this occur, your vote will directly have an impact on the Company's future direction and the value your investment ultimately generates.